Assessment of Daily Replanning and Geometrical Variation of High-dose-rate Brachytherapy for the Prostate.
HDR-BT
Prostate cancer
brachytherapy
daily replanning
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
14
01
2020
revised:
24
01
2020
accepted:
27
01
2020
entrez:
6
3
2020
pubmed:
7
3
2020
medline:
16
4
2020
Statut:
ppublish
Résumé
The present study aimed to estimate geometric changes in applicators and prostate over 3 days in patients with high-dose-rate brachytherapy (HDR-BT) and to assess the need for daily replanning. This study retrospectively investigated 18 patients who underwent HDR-BT as monotherapy from February 2016 to October 2018. Without replanning, the planning target volume coverage significantly worsened on day 2 (p<0.001) and day 3 (p=0.003). The minimum dose distributed to the highest irradiated rectal volume of 5 cc became significantly higher on day 2 (p=0.02), and the maximum dose distributed to the urethra became significantly higher on day 2 (p=0.01). Conformal, high-dose delivery of HDR-BT is impaired without replanning not only on the second day but also on the third day. Daily replanning is required for achieving accuracy of HDR-BT.
Sections du résumé
BACKGROUND
BACKGROUND
The present study aimed to estimate geometric changes in applicators and prostate over 3 days in patients with high-dose-rate brachytherapy (HDR-BT) and to assess the need for daily replanning.
PATIENTS AND METHODS
METHODS
This study retrospectively investigated 18 patients who underwent HDR-BT as monotherapy from February 2016 to October 2018.
RESULTS
RESULTS
Without replanning, the planning target volume coverage significantly worsened on day 2 (p<0.001) and day 3 (p=0.003). The minimum dose distributed to the highest irradiated rectal volume of 5 cc became significantly higher on day 2 (p=0.02), and the maximum dose distributed to the urethra became significantly higher on day 2 (p=0.01).
CONCLUSION
CONCLUSIONS
Conformal, high-dose delivery of HDR-BT is impaired without replanning not only on the second day but also on the third day. Daily replanning is required for achieving accuracy of HDR-BT.
Identifiants
pubmed: 32132074
pii: 40/3/1677
doi: 10.21873/anticanres.14119
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1677-1682Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.